Study of the JAK Inhibitor Ruxolitinib Administered Orally to Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia-Myelofibrosis (PET-MF)

NCT01317875 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

69

Enrollment

INDUSTRY

Sponsor class

Conditions

Myelofibrosis

Interventions

DRUG: Ruxolitinib

Sponsor

Incyte Corporation

Collaborators

[object Object]